Drug Profile
Onternabez - Panag Pharma/Tetra Bio Pharma
Alternative Names: ARDS-003; HU-308; PPP-003; PPP-003 Covid product - Tetra Bio-PharmaLatest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator Panag Pharma
- Developer Panag Pharma; Tetra Bio Pharma
- Class Alcohols; Analgesics; Anti-infectives; Anti-inflammatories; Cannabinoids; Eye disorder therapies; Small molecules; Urologics
- Mechanism of Action Cannabinoid receptor CB2 agonists; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dry eyes; Uveitis
- Preclinical Cytokine release syndrome; Proliferative vitreoretinopathy; SARS-CoV-2 acute respiratory disease; Sepsis
- Research Renal failure
Most Recent Events
- 29 Nov 2022 Tetra Bio Pharma has patent pending for Onternabez in USA and files Patent Cooperation Treaty (PCT) patent application for Onternabez
- 06 Sep 2022 Tetra Bio Pharma collaborates with Cellvera for onternabez for the treatment of COVID-2019 infections
- 10 Aug 2022 Pharmacodynamics data from a preclinical trial in SARS-COV-2 acute respiratory disease released by Tetra Bio Pharma